The present invention provides bioerodable constructs for controlled release of bioactive materials. In a preferred mode, the constructs may be utilized adjacent to a biological surface. The constructs are based on a blend of two or more poly(ester-amide) polymers (pea). Such polymers may be prepared by polymerization of a diol (D), a dicarboxylic acid (C) and an alpha-amino acid (A) through ester and amide links in the form (DACA)n. An example of a (DACA)n polymer is shown below in formula II. Suitable amino acids include any natural or synthetic alpha-amino acid, preferably neutral amino acids.

Patent
   RE40359
Priority
Jan 11 2000
Filed
Mar 08 2006
Issued
Jun 03 2008
Expiry
Jan 11 2021
Assg.orig
Entity
Large
6
31
all paid
0. 26. A bioerodable construct for controlled release of bioactive materials, said construct comprising a blend of at least two poly(ester-amide) polymers (pea), wherein each pea polymer has the formula: ##STR00004##
wherein
k=2-12,
m=2-12, and
R=CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, (CH2)3CH3, CH2C6H5, or (CH2)2SCH3,
wherein the blend comprises a pea polymer wherein R=CH2CH(CH3)2 or a pea polymer wherein R=CH2C6H5.
1. A bioerodable construct for controlled release of bioactive materials, said construct comprising a blend of at least two poly(ester-amide) polymers (pea) prepared by polymerizing a diol (D), wherein the diol (D) is not bisphenol; a dicarboxylic acid (C), wherein the dicarboxylic acid (C) is not phthalic acid; and an alpha-amino acid (A) through ester and amide links in the form (DACA)n. ,
wherein the pea polymer has the formula: ##STR00003##
wherein
k=2-12,
m=2-12, and
R=CH2CH(CH3)2, or CH2C6H5.
and,
wherein the blend comprises a first pea polymer in which A is phenylalanine (Phe-pea) and a second pea polymer in which A is leucine (leu-pea) at a ratio of Phe-pea to leu-pea is from of 10:1 to 1:1.
0. 58. A bioerodable construct for controlled release of bioactive materials, said construct comprising a blend of at least two poly(ester-amide) polymers (pea), wherein each pea polymer has the formula: ##STR00005##
wherein
k=2-12,
m=2-12,
wherein r represents an amino acid side chain, and the amino acid side chain is selected from aliphatic side chains, sulfur-containing side chains, and side chains containing aromatic rings, and
wherein the blend comprises a pea polymer wherein r is an amino acid side chain containing an aromatic ring or a pea polymer wherein r is an aliphatic amino acid side chain.
0. 53. A bioerodable construct for controlled release of bioactive materials, said construct comprising a blend of at least two poly(ester-amide) polymers (pea) prepared by polymerizing a diol (D), wherein the diol (D) is not bisphenol; a dicarboxylic acid (C), wherein the dicarboxylic acid (C) is not phthalic acid; and an alpha-amino acid (A) through ester and amide links in the form (DACA)n, wherein the alpha-amino acid (A) of each pea polymer of the blend is selected from the group of amino acids having aliphatic side chains, amino acids having sulfur-containing side chains, and amino acids having side chains containing aromatic rings, and wherein the alpha-amino acid of at least one of the pea polymers is phenylalanine or leucine.
0. 2. The construct of claim 1, wherein k=2, 3, 4, and 6 and m=4 or 8.
3. The construct of claim 1, wherein the ratio of Phe-pea to leu-pea is 5:1 to 2.5:1.
4. The construct according to any one of claims 1,2 or 3, wherein the construct is a deformable sheet adapted to conform to a biological surface.
5. The construct according to claim 4, further comprising a bioactive agent.
6. The construct of claim 5, wherein the bioactive agent is selected from the group consisting of antiseptics, anti-infectives, such as bacteriophages, antibiotics, antibacterials, antiprotozoal agents, and antiviral agents, analgesics, anti-inflammatory agents including selected from the group consisting of steroids and non-steroidal anti-inflammatory agents including selected from the group consisting of COX-2 inhibitors, anti-neoplastic agents, contraceptives, CNS active drugs, hormones, and vaccines.
7. The construct according to claim 5, wherein the construct comprises an enzyme capable of hydrolytically cleaving the pea polymer.
8. The construct according to claim 7, wherein the enzyme is α-chymotrypsin.
9. The construct according to claim 7, wherein the enzyme is adsorbed on the surface of the construct.
10. The construct according to claim 7, wherein the construct contains a bacteriophage which are is released by action of the enzyme.
11. A method of treating a patient having an ulcerative wound comprising inserting into the wound or covering the wound with a bioerodable construct according to claim 1, wherein the bioerodable construct is a deformable sheet containing a bioactive agent.
12. The method of claim 11, wherein the bioactive agent is comprises a bacteriophage, an antibiotic, an antiseptic, or an analgesic.
13. The method of claim 11, wherein the wound is open or infected.
14. The method according to claim 12, wherein the bacteriophage are specific for bacteria found in the wound.
15. The method according to any one of claim claims 11-14, wherein the construct also comprises an enzyme capable of hydrolytically clearing the pea polymer.
16. The construct according to any one of claims 1, 2 or 3, further comprising a bioactive agent.
17. The construct of claim 16, wherein the bioactive agent is selected from the group consisting of antiseptics, anti-infectives, such as bacteriophages, antibiotics, antibacterials, antiprotozoal agents, and antiviral agents, analgesics, anti-inflammatory agents including selected from the group consisting of steroids and non-steroidal anti-inflammatory agents including selected from the group consisting of COX-2 inhibitors, anti-neoplastic agents, contraceptives, CNS active drugs, hormones, and vaccines.
18. The construct according to any one of claims 1, 2 or 3, wherein the construct comprises an enzyme capable of hydrolytically cleaving the pea polymer.
19. The construct according to claim 18, wherein the enzyme is α-chymotrypsin.
20. The construct according to claim 18, wherein the enzyme is adsorbed on the surface of the construct.
21. The construct according to claim 18, wherein the construct contains a bacteriophage which are is released by action of the enzyme.
0. 22. The construct according to claim 1 wherein the blend is formed into a bioerodable coating on a support material or is formed into a bioerodable film.
0. 23. The construct according to claim 22 wherein the blend is formed into a bioerodable coating comprising bioactive material.
0. 24. The construct according to claim 1 wherein the construct is a device that can be surgically implanted.
0. 25. The construct according to claim 24 wherein the implantable device is an indwelling catheter or appliance for oral hygiene.
0. 27. The construct according to claim 26, wherein the blend comprises a first pea polymer wherein R=CH2CH(CH3)2, and a second pea polymer wherein R=CH2C6H5.
0. 28. The construct of claim 27, wherein the first pea polymer and second pea polymer are present in a ratio of 10:1 to 1:1.
0. 29. The construct of claim 28, wherein the ratio of first pea polymer to second pea polymer is 5:1 to 2.5:1.
0. 30. The construct of claim 26, wherein k=2, 3, 4, or 6 and m=4 or 8.
0. 31. The construct according to claim 26, wherein the construct is deformable sheet adapted to conform to a biological surface.
0. 32. The construct according to claim 31, further comprising a bioactive agent.
0. 33. The construct of claim 32, wherein the bioactive agent is selected from the group consisting of antiseptics, anti-infectives, bacteriophages, antibiotics, antibacterials, antiprotozoal agents, and antiviral agents, analgesics, anti-inflammatory agents selected from the group consisting of steroids and non-steroidal anti-inflammatory agents selected from the group consisting of COX-2 inhibitors, anti-neoplastic agents, contraceptives, CNS active drugs, hormones, and vaccines.
0. 34. The construct according to claim 32, wherein the construct comprises an enzyme capable of hydrolytically cleaving the pea polymer.
0. 35. The construct according to claim 34, wherein the enzyme is α-chymotrypsin.
0. 36. The construct according to claim 34, wherein the enzyme is adsorbed on the surface of the construct.
0. 37. The construct according to claim 34, wherein the construct contains a bacteriophage which is released by action of the enzyme.
0. 38. A method of treating a patient having an ulcerative wound comprising inserting into the wound or covering the wound with a bioerodable construct according to claim 26, wherein the bioerodable construct is a deformable sheet containing a bioactive agent.
0. 39. The method of claim 38, wherein the bioactive agent comprises a bacteriophage, an antibiotic, an antiseptic, or an analgesic.
0. 40. The method of claim 38, wherein the wound is open or infected.
0. 41. The method according to claim 39, wherein the bacteriophage is specific for bacteria found in the wound.
0. 42. The method of claim 38, wherein the construct also comprises an enzyme capable of hydrolytically cleaving the pea polymer.
0. 43. The construct according to claim 26 further comprising a bioactive agent.
0. 44. The construct of claim 43, wherein the bioactive agent is selected from the group consisting of antiseptics, anti-infectives, bacteriophages, antibiotics, antibacterials, antiprotozoal agents, and antiviral agents, analgesics, anti-inflammatory agents selected from the group consisting of steroids and non-steroidal anti-inflammatory agents selected from the group consisting of COX-2 inhibitors, anti-neoplastic agents, contraceptives, CNS active drugs, hormones, and vaccines.
0. 45. The construct according to claim 26, wherein the construct comprises an enzyme capable of hydrolytically cleaving the pea polymer.
0. 46. The construct according to claim 45, wherein the enzyme is α-chymotrypsin.
0. 47. The construct according to claim 45, wherein the enzyme is adsorbed on the surface of the construct.
0. 48. The construct according to claim 45, wherein the construct contains a bacteriophage which is released by action of the enzyme.
0. 49. The construct according to claim 26 wherein the blend is formed into a bioerodable coating on a support material or is formed into a bioerodable film.
0. 50. The construct according to claim 49 wherein the blend is formed into a bioerodable coating comprising bioactive material.
0. 51. The construct according to claim 26 wherein the construct is a device that can be surgically implanted.
0. 52. The construct according to claim 51 wherein the implantable device is an indwelling catheter or appliance for oral hygiene.
0. 54. The construct of claim 53 wherein the amino acid having aliphatic side chains is selected from valine, leucine, isoleucine, and norleucine.
0. 55. The construct of claim 53, wherein the amino acid having sulfur-containing side chains is methionine.
0. 56. The construct of claim 53, wherein the amino acid having side chains containing aromatic rings is phenylalanine.
0. 57. The construct of claim 53 the blend comprises a first pea polymer in which A is phenylalanine and a second pea polymer in which A is leucine.
0. 59. The construct of claim 58 wherein the aliphatic amino acid side chain is selected from valine, leucine, isoleucine, and norleucine side chains.
0. 60. The construct of claim 58, wherein the sulfur-containing side chain is a methionine side chain.
0. 61. The construct of claim 58, wherein the side chain containing aromatic rings is a phenylalanine side chain.
0. 62. The construct of claim 58 the blend comprises a first pea polymer in which r is a phenylalanine side chain, and a second pea polymer in which r is a leucine side chain.
0. 63. The construct according to claim 1 wherein the construct is a device for wound packing.
0. 64. The construct according to claim 63 wherein the construct is a foam.
0. 65. The construct according to claim 53 wherein the construct is a device for wound packing.
0. 66. The construct according to claim 65 wherein the construct is a foam.

This application claims benefit of Provisional Application No. 60/175,377 filed on Jan. 11, 2000 Compositites Composites made of bioerodable polymers disappear over time in a biological environment as the substance of the composite is egraded degraded or dissolved by action of the surrounding biologic milieu. This degradation may be facilitated by enzymes which catalyze cleavage of covalent bonds in the polymer. (Such enzymes may be present in the bilologic mileu biologic milieu or may be added exogenously, whether as part of the construct or otherwise.) Controlled or sustained release of a biologically active substance from a bioerodable construct refers to a delay in the dispersion of the biologically active substance relative to simple diffusion from its point of introduction into the biological environment. Controlled release is generally due to some factor which interferes with normal diffusion of the substance, such as a diffusion barrier or limited solubility of the diffusion substance. The bioerodable constructs of this invention present a diffusion barrier which is removed progressively as the polymer degrades.

More recently, it has also been established that the rapid release of polymer degradation products in a sufficient amount into the surrounding tissues activates macrophages for the production of growth factors, which may accelerate wound healing. It is beneficial for polymeric degradation products to be either normal metabolic components or easily digestible by cells. Polymers used as matrices should be plastic enough to tightly cover wounds. It is also highly desirable for the polymeric matrix to be able either to immobilize enzymes (e.g. trypsin, alpha-chymotrypsin, lipase, etc.) on the surface by a simple method or incorporate them in the bulk matrix. These enzymes can participate in the wound healing processes and can also erode polymers (e.g., by catalyzing the hydrolysis of ester bonds in the polymeric backbone) with a constant and desirable rate to provided for the release of bactericidal compounds as well as sufficient matrix degradation products in the surrounding tissue to stimulate macrophages.

The inventor has synthesized new biodegradable poly (ester-amide)s (PEAs) composed of naturally occurring alpha-amino acids, including essential ones like L-phenylalanine and L-leucine, and nontoxic compounds like aliphatic and dicarboxylic acids. Suitable synthetic methods are reported in Arabuli, et al. (1994), “Heterochain Polymers based on Natural Amino Acids. Synthesis and enzymatic hydrolysis of regular poly(ester-amide)s based on bis-(L-phenylalanine) alpha,omega-alkylene diesters and adipic acid,” Macromol. Chem. Phys., 195(6):2279, and Katsarava, et al. (1998) “Amino Acid Based Bioanalogous Polymers. Synthesis and study of regular poly(ester-amide)s based on bis-(α-amino acid) α,ω-alkylene diesters and aliphatic dicarboxylic acid”, J. Polym. Sci.: Part A: Chemistry, 37:391-407, the entirety of which are incorporated herein by reference. These rapidly bioresorbable, biocompatible poly(ester-amide)s may be used to form a bioerodable polymer matrix.

The poly(ester-amides) of this invention do not contain any toxic components. Alpha-amino acids, such as the essential amino acids L-phenylalanine and L-leucine, are naturally-occurring products. These normal metabolic components, upon release through biodegradation, are digested by cells. Fatty acids and diols are well known nontoxic products commonly used in the food industry. They are also used as building blocks for other classes of biodegradable polymers like poly anhydrides and poly-(ortho-ester)s approved by the U.S. Food and Drug Administration (FDA) for clinical trials and other practical applications.

It is very important that the poly(ester-amide)s used in this invention are soluble in organic solvents that do into inactivate bioactive compounds such as bacteriophages. These polymers are soluble in chloroform in which the enzymes like trypsin, α-chymotrypsin, lipase are sufficiently stable for enzyme activity to survive the process of preparing enzyme-containing polymer constructs.

Enzymes can be added to polymeric solutions in chloroform in order to form enzyme-containing polymeric matrices when the solution is cast onto glass plates and the solvent is evaporated. For polymeric films impregnated by enzymes according to this method, the enzymes catalyze the hydrolysis (erosion) of PEAs, which is important for the release of bioactive substances into the surrounding tissues. The biodegradation rates of PEAs can vary over a wide range, spanning, e.g., 101-103 mg/cm2 h. The degradation rate is a function of the enzyme activity in the composite. These polymers may be designed to release sufficient matrix degradation products (polymeric debris) over time to activate macrophages.

Enzymes may be spontaneously immobilized onto the surface of PEAs based on L-phenylalanine through the simple immersion of the polymeric films in aqueous enzyme solution for varying lengths of time. (Immersion for, e.g., for 15-20 min is typical.) PEAs based on L-leucine do not readily absorb enzymes using this simple method, and thus, PEAs based on L-phenylalanine are more suitable for preparing biodegradable matrices with surface-immobilized enzymes. However, PEAs based on L-phenylalanine do not possess sufficient plasticity for use as wound coverings. PEAs composed of L-leucine are pliable when hydrated (i.e., water acts as a plasticizer) and more suitable for biological applications such as wound coverings (dressings); however the films prepared from L-leucine PEAs are very sticky, adhering to themselves, and inconvenient to work with. In addition, L-leucine based PEAs immobilize enzymes poorly.

The present invention has discovered that the detrimental characteristics inherent in each class of PEAs can be overcome by blending them. Polymeric blends prepared from approximately 70% of L-phenylalanine based PEAs and 30% of L-leucine based PEAs showed:

    • good plasticity (necessary to cover wounds tightly),
    • lack of self-adhesion, and
    • ability to immobilize enzymes.

As contemplated by the present invention, the polymer blend which is the basis for the invention has sufficient plasticity to permit a film made with the polymer blend to be manually deformed to fit tightly to an irregular biological surface (e.g., a concave wound surface). Additionally, films made with the polymer blend are readily separable by gentle manual force, leaving each sheet of film intact upon separation. Finally, the surface of an object made with the polymer blend of this invention will absorb proteins, such that measurable enzyme activity can be detected adhered to the surface of the object after it is dipped into a solution of the enzyme.

This invention provides polymer blends comprising at least two PEAs of formula II. Preferably the blend contains one PEA in which R corresponds to the side chain of phenylalanine (Phe-PEA) and one PEA in which R corresponds to the side chain of leucine (Leu-PEA). The ratio of Phe-PEA to Leu-PEA may vary from 10:1 to 1:1, but is preferably from 5:1 to 2.5:1. Other PEAs (and indeed other polymers) may be included in the blend, so long as the resultant blend still exhibits the desired properties described above. The other polymers in the blend will, of course, be soluble in the solvent in which the blend is dispersed for preparing the constructs according to this invention. Leu-PEA and Phe-PEA are soluble in polar organic solvents including dimethyl-formamide (DMF), dimethylacetamide, dimethylsulfoxide (DMSO), trifluoroethanol, hexafluoroisopropanol and the like, or neutral organic solvents including chloroform and the like. Chloroform and similar solvents are preferred for preparation of bioerodable films containing bioactive components due to greater volatility (important for preparing films) and reduced tendency to inactivate enzymes (such as chymotrypsin or lipase), bacteriophages or other bioactive components.

In a preferred mode, the polymer blend of this invention is formed into a bioerodable film. The films of this invention may be a single layer or multiple layers, such as a bilayer film having one layer of a PEA blend and an adjacent layer of poly(siloxane elastomer). However, alternative bioerodable constructs using the polymer blend are easily within the skill of the art and within the contemplation of this invention. For example, the polymer blend may be used to provide a bioerodable coating on a support material which may or may not be biodegradable, such as a fibrous or non-fibrous three-dimensional construct or a woven support. Suitable forms for the three-dimensional constrcts constructs of this invention are foams, which may be formed by conventional means. For example, Phe-PEA/Leu-PEA blends can be prepared as foams as follows: a suspension of bacteriophages and other bioactive substanses substances (about 1 g) in the solution of Phe-PEA/Leu-PEA blend (1 g) in chloroform (10 mL) can be cast onto hydrophobic surface and 90-99% of chloroform evaporated at r.t. under atmospheric pressure. Afterwards a reduced pressure may be applied at room temperature to remove residual chloroform, and the resulting foamed film dried for 12 h under reduced pressure. According to another procedure 1-10% (of chloroform volume) of n-pentane may be added to the suspension above. The mixture may be cast onto a hydrophobic surface and allowed to dry at room temperature for 24 h, and the foamed film may be subjected to a final drying under reduced pressure for 12 h. Foamed films may also be obtained using ultrasonic disintegration techniques.

Constructs prepared with the polymers of this invention may be part of devices including a support material to be used as, for example, bandages for wounds or burn dressings. Of course, the blends forming a coating on a woven support will preferably retain the flexibility and/or elasticity of blends used for film-forming, but a blend for coating a rigid, three-dimensional construct may be less elastic. Such blends may have higher Phe-PEA content, and coatings in which Phe-PEA is the only PEA polymer are within the contemplation of this invention for such applications.

In another mode, this invention contemplates constructs consisting all or in part of a blend according to this invention which may be surgically implanted. Constructs according to this invention may also be formed into devices for wound packing, such as gel foams, or may be used as components in surgical appliances, such as Penrose drains, indwelling catheters, catheters for peritoneal dialysis, and any other appliances that are in contact with body cavities, the blood circulation, or the lymphatic circulation and are either used to treat potential infections or are at risk of becoming infected. This invention also contemplates appliances for oral hygiene, including gum implants (e.g., for periodontal disease or dental caries). Such constructs will preferably contain bioactive material released in a controlled manner upon erosion of the construct. Suitable selections of particular bioactive inclusions will be readily apparent to the skilled artisan in view of the intended site of implantation. For example, composites containing bactericidal agenst agents such as bacteriophage may be implanted in the body to treat osteomyelitis, etc. Alternatively, bioerodable composites of this invention could be used for sustained/controlled release of anticancer and/or other drugs at a target site. Bioactive materials may be released in a controlled fashion by diffusion from within the construct, or by degradation of the construct, or by a combination of these processes.

Bioactive and/or inactive biocompatible materials may be included in the erodable construct in amounts up to 60% or more by weight, so long as their inclusion does not destroy the desirable properties of films according to this invention. Bioactive materials contemplated for inclusion in the bioerodable constructs of this invention include, but are not limited to, antiseptics, anti-infectives, such as bacteriophages, antibiotics, antibacterials, antiprotozoal agents, and antiviral agents, analgesics, anti-inflammatory agents including steroids and non-steroidal anti-inflammatory agents including COX-2 inhibitors, anti-neoplastic agents, contraceptives, CNS active drugs, hormones, and vaccines. In particular, constructs may include one or more of calcium gluconate and other phage stabilizing additives, hyaluronidase, fibrinolysine and other fibrinolytic enzymes, methyluracyl and other agents stimulating metabolic processes, sodium hydrocarbonate, L-arginine and other vasodilators, Benzocaine and other pain killers, mono- and disaccharides, polysaccharides and mucopolysaccharides, Metronidazol and other anti-protozoa drugs, Clotrimazolum and other anti-fungal drugs, thrombine and other hemostatics, vitamins, Prednizolone and other anti-inflammatory steroids, and Voltaren (Sodium diclofenac) and other anti-inflammatory non-steroid drugs. Of course the skilled artisan will in any case confirm that particular construct formulations retain the desired properties as discussed herein, and constructs which exhibit none of these properties are outside the contemplation of this invention.

In one preferred mode, this invention provides a novel approach to management of poorly healing and poorly vascularized wounds (which may include diabetic foot ulcers, pressure ulcers in patients with reduced mobility, and other ulcers and open skin lesions lesions). In medicine, poorly healing wounds, such as those seen in diabetic patients with foot ulcers, and in bedridden patients with pressure sores, represent a major and very expensive management problem. Use of antibiotics in this setting is generally not efficacious. Because of poor vascularization, antibiotics seldom achieve therapeutic levels in affected areas sufficient to eradicate infection. Moreover, because of the recurrent courses of antibiotics that such patients have often received, the bacterial pathogens causing the infections are often antibiotic resistant. In this mode, as well as other wound treatment embodiments, the controlled-release character of the polymer constructs according to this invention avoid the necessity of constant re-application of bactericidal material, as well as the need for associated dressing changes.

Biocomposites mediating a sustained/controlled release of appropriate therapeutic agents have proven to be especially efficacious for healing infected wounds and cavities. Film materials, so called “artificial skin”, prepared from these biocomposites have important therapeutic effects:

    • Polymer material, when applied to the surface of such wounds, acts as a protector from external mechanical actions and bacterial invasion, and further prevents heat and moisture loss that occur as a result of uncontrolled water evaporation from the injured surface; and
    • The slow-release properties of the biologically-active compound can be exploited to promote appropriate, steady release of anti-bacterial agents at the site of infection.

Use of biocomposite “artificial skin” does not require patient immobilization, and thereby facilitates a return to daily life activities, an important consideration in this class of patients.

A key element in the management of chronically infected wounds is the suppression of pathogenic bacterial flora. With biocomposite materials, this can be achieved by introducing bacteriocidal substances into the biocomposite structure. Antibiotics may be used in this setting, but their efficacy is increasingly limited by the development of antibiotic resistance. More recently, there has been interest in the introduction into biocomposites of such bactericidal substances as silver sulfadiazine (and related diazine derivatives of sulfanilamide), furagin (and pharmaceutically acceptable salts thereof) and chlorohexydine (and pharmaceutically acceptable salts thereof). However, utilization of such compounds may be limited by their inherent toxicity, particularly for patients with underlying kidney or liver disease.

Incorporation of bacteriophages into such biocomposite materials provides an alternative approach. Bacteriophage are viruses that kill specific bacteria. The lysis of microorganisms by viruses was discovered at the beginning of the 20th century. Any one phage tends to be highly specific for certain bacteria, requiring that therapy be carefully targeted (i.e., there is no analogy to the broad-spectrum antibiotics which can “kill everything”). However, this also means that phage therapy can be used to kill specific pathogens without disturbing normal bacterial flora.

Phages have been reported to be effective in treating skin infections caused by Pseudomonas, Staphylococcus, Klebsiella, Proteus, E. coli, and other pathogenic species; success rates in these studies have ranged from 75 to 100%, depending on the pathogen. However, for these studies bacteriophages were introduced in a variety of vehicles: aqueous liquid preparations, aerosols and creams.

The polymeric blend composed of L-phenylalanine, L-leucine, adipic acid, and butane-diol-1,4 has been successfully used for preparing bioactive composites containing bactericidal substances. The wound dressings obtained based on this biocomposite material showed high wound healing properties.

Starting from the materials mentioned above it seems that bioactive composite based on bioresorbable (bioerodable) polymer and containing a complex of bacteriophages as a bactericidal substance will be an effective dressing material with accelerated wound healing ability. Selection of suitable bacteriophage is described in U.S. Provisional Patent Application No. 60/175,415, entitled “Bacteriophage Specific for Vancomycin Resistant Enterococci (VRE)”, filed Jan. 11, 2000, and U.S. Provisional Patent Application Nos. 60/175, 416, filed Jan. 11, 2000, and 60/205,240, filed May 19, 2000, both entitled “Method And Device For Sanitation Using A Bacteriophage”, the disclosures of which are incorporated by reference in their entireties.

A complex of polyvalent bacteriophages directed toward Staphylococcus species, Streptococcus species, E. coli, Proteus species, and Pseudomonas aeruginosa with a titer of 2×106-2×107 plaque-forming units, was prepared and used as bioactive substance for this study. Bacteriophage were prepared as a lyophilized dry powder as follows: bacteriophages suspended in an aqueous sucrose-gelatin mixture were lyophilized, resulting in a dry mass that was ground into fine powder. In this process, 50 mg of dry preparation corresponds to 1 ml of liquid bacteriophage with a titer of 2×106-2×107. None of the individual components of bioactive composites (polymer, organic solvent, alpha-chymotrypsin, lipase) affected bacteriophages activity—100% of starting activity was retained in all cases.

A bioactive film was prepared as follows: A fine suspension of dry bacteriophage in a polymer solution with an appropriate solvent was cast on a glass surface and dried to constant weight. A composite was obtained in the from of a film with the following characteristics: mass 1 g, film area—65-65 cm2, thickness—0.2-0.3 mm. Afterwards alpha-chymotrypsin was immobilized on the surface of the film. Optionally, the film was perforated. For particular applications, analgesics and/or antibiotics were added to the composite as well.

The activity of the resultant film in in vitro experiments was determined using a bacterial lawn on solid media. Activity was estimated by measuring the width of the zone of lysis. The activity of the film coincides with the activity of dry bacteriophages used; pure polymeric film did not reveal any bactericidal activity.

The kinetics of bacteriophage release from 9 cm disks of the film was studied in phosphate buffer under physiological conditions (see Table 1). One can see that release of bacteriophages during first 24 hours both from α-chymotrypsin-immobilized and α-chymotrypsin-free films was comparable; for enzyme-immobilized film it was only 1.5-2 times higher. This can be explained by extensive desorption of bacteriophages from the surface zone of enzyme free film. However, when the films were transferred to fresh buffer at 24 hours and 120 hours, the enzyme-catalyzed erosion mechanism became important at later stages for releasing bacteriophages from the bulk of the film, and difference in release rate reached more than one order in magnitude. Clearly, alpha-chymotrypsin promotes the release of bacteriophages from bioactive composite.

TABLE
Sustained Release of Bacteriophages and Antibiotics from
Medicated Wound Covering Film
Release of bacteriophages from 9 cm dia. Phe-PEA film disks into 10 mL
of Phosphate buffer 0.2 M, pH 7.4, T = 37° C. A 9 cm Phe-PEA/bacterio-
phage film disk contains approximately 1800 × 104 bacteriophages.
Titer of bacteriophages in 1 mL solution
Composite
Composite bacteriophage/Phe-PEA film
Time in bacteriophage/Phe-PEA without surface-immobilized
hours film with α-chymotrypsin α-chymotrypsin
1 2.0 × 104 1.3 × 104
3 5.0 × 104 3.0 × 104
24 8.0 × 104 4.0 × 104

24 h later, after transfer to a new 10 mL portion of the buffer

1 3.2 × 104 1.3 × 104
3 9.0 × 104 3.1 × 104
96 200.0 × 104 90.0 × 104

120 h later, after transfer to a new 10 mL portion of the buffer

Composite
Composite bacteriophage/Phe-PEA film
Time in bacteriophage/Phe-PEA without surface-immobilized
hours film with α-chymotrypsin α-chymotrypsin
1 2.5 × 104 0.06 × 104
4 5.0 × 104 0.20 × 104

It should be noted that surface immobilized α-chymotrypsin can play an additional role namely it can decompose both peptides and denaturated proteins. this enzymatic debridment, as it is known from literature, leads to the sanitation of a wound and accelerates healing.

The activity of films according to this invention was checked periodically for 1.5 years against both preexisting laboratory strains and newly received bacterial strains, and the film retained activity over this period. The surface immobilized enzyme was active for this period as well. The FIGURE shows lipase catalyzed biodegradation of polymers in vivo over a six month period. The in vivo data is summarized in Table 2.

TABLE 2
In vivo Degradation of Biocomposites
Number
Number of films
of per one Duration
Sample rats rat (days) Result
4-L-Phe-4 2 2 109 Films were completely absorbed, in one case a trace of connective tissue capsule
was observed.
4-L-Phe-4 2 2 123 Films were completely absorbed, no trace of tissue reaction was observed
4-L-Phe-4 2 2 175 Films were completely absorbed, no trace of tissue reaction was observed.
4-L-Phe-4-Lip 3 2 39 In 2 rats films were completely absorbed, in one rat both films were
incapsulated* encapsulated*.
4-L-Phe-4-Lip 1 2 42 Films were completely absorbed, no trace of tissue reaction was observed.
4-L-Phe-4-Lip 4 4 44 Films were completely absorbed, no trace of tissue reaction was observed.
4-L-Phe-4-Lip 1 2 45 Both films were incapsulated* encapsulated*.
4-L-Phe-4-Lip 5 3 77 14 films were completely absorbed, only one film was
incapsulated* encapsulated*.
4-L-Phe-4-Lip 2 2 145 Films were completely absorbed, no trace of tissue reaction was observed.
*In these cases lipase was found to be inactivated, that is it did not catalyze the hydrolysis of poly(ester amide).
Totally 57 films (each 20-25 mg) were implanted subcutaneously to into rats, 52 films were completely absorbed. Only 5 films of 4-L-Phe-4-Lip series were incapsulated encapsulated owing to enzyme inactivation.
4-L-Phe-4-PEA based on L-phenylalanine, adipic acid, and butanediol-1,4,4-L-Phe-4-Lip - the same, lipase impregnated (10 mg lipase per 1 g of PEA).

Katsarava, Ramaz, Alavidze, Zemphira

Patent Priority Assignee Title
10596355, Jun 30 2010 Surmodics, Inc Catheter assembly
11318204, Dec 30 2010 Surmodics, Inc. Composition for intravascular delivery of therapeutic composition
8034364, Jul 13 2006 Advanced Cardiovascular Systems, Inc. Implantable medical device comprising a pro-healing(ester-amide)
8927000, Jun 30 2010 Surmodics, Inc Lipid coating for medical devices delivering bioactive agent
8961457, Sep 30 2010 Surmodics, Inc Catheter assembly with guard
9375519, Jun 25 2012 Surmodics, Inc Bioerodable poly(etheresteramides) and medical article uses
Patent Priority Assignee Title
3493652,
3867520,
4351337, May 17 1973 CRYOGENIC TECHNOLOGY, INC Biodegradable, implantable drug delivery device, and process for preparing and using the same
4414202, Feb 19 1980 LANGE MEDICAL PRODUCTS, INC ; LANGE VENTURE PARTNERS, L P ; LANGE ASSOCIATES LIMITED PARTNERSHIP; WOUNDCARE ACQUISITION LLC Composition for treatment of wounds
4778679, Feb 19 1980 LANGE MEDICAL PRODUCTS, INC ; LANGE VENTURE PARTNERS, L P ; LANGE ASSOCIATES LIMITED PARTNERSHIP; WOUNDCARE ACQUISITION LLC Method and composition for treatment of wounds
4835248, May 15 1986 Hoechst Aktiengesellschaft Biologically degradable polyamide for depot preparations having controlled release of the active compound
4876242, Sep 21 1987 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
5093319, Oct 31 1989 Stryker Technologies Corporation Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
5306620, Jul 08 1987 SCRIPPS RESEARCH INSTITUTE, THE, A CORP OF CA Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
5380656, Apr 28 1989 BOOTS COMPANY PLC, THE Chymopapain and method of purifying it on an inhibitory dipeptide affinity column
5386003, Mar 15 1993 Eastman Chemical Company Oil absorbing polymers
5399665, Nov 05 1992 CHILDREN S MEDICAL CENTER CORPORATION Biodegradable polymers for cell transplantation
5468480, Apr 28 1989 The Boots Company PLC Pharmaceutical composition of purified chymopapain
5658592, May 13 1994 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
5770229, May 13 1994 Kuraray Co., Ltd. Medical polymer gel
5902875, Jan 28 1997 United States Surgical Corporation Polyesteramide, its preparation and surgical devices fabricated therefrom
5914387, Jan 28 1997 United States Surgical Corporation Polyesteramides with amino acid-derived groups alternating with alpha-hydroxyacid-derived groups and surgical articles made therefrom
5919893, Jan 28 1997 United States Surgical Corporation Polyesteramide, its preparation and surgical devices fabricated therefrom
6503538, Aug 30 2000 Cornell Research Foundation, Inc Elastomeric functional biodegradable copolyester amides and copolyester urethanes
EP47719,
EP560014,
EP712635,
EP447719,
EP560014,
EP712635,
JP4103566,
WO9832398,
WO9832777,
WO3062298,
WO9832398,
WO9832777,
//////////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Mar 08 2006Surmodics, Inc.(assignment on the face of the patent)
Oct 14 2022SURMODICS MD OPERATIONS, LLCMIDCAP FUNDING IV TRUSTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0687620423 pdf
Oct 14 2022SURMODICS IVD, INC MIDCAP FUNDING IV TRUSTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0687620423 pdf
Oct 14 2022SURMODICS COATINGS MFG, LLCMIDCAP FUNDING IV TRUSTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0687620423 pdf
Oct 14 2022Surmodics MD, LLCMIDCAP FUNDING IV TRUSTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0687620423 pdf
Oct 14 2022SURMODICS COATINGS, LLCMIDCAP FUNDING IV TRUSTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0687620423 pdf
Oct 14 2022SURMODICS HOLDINGS, LLCMIDCAP FUNDING IV TRUSTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0687620423 pdf
Oct 14 2022SURMODICS SHARED SERVICES, LLCMIDCAP FUNDING IV TRUSTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0687620423 pdf
Oct 14 2022Surmodics, IncMIDCAP FUNDING IV TRUSTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0687620423 pdf
Oct 14 2022NORMEDIX, INC MIDCAP FUNDING IV TRUSTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0687620423 pdf
Date Maintenance Fee Events
Oct 24 2011REM: Maintenance Fee Reminder Mailed.
Mar 01 2012M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Mar 01 2012M1555: 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity.
Sep 09 2015M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Jun 03 20114 years fee payment window open
Dec 03 20116 months grace period start (w surcharge)
Jun 03 2012patent expiry (for year 4)
Jun 03 20142 years to revive unintentionally abandoned end. (for year 4)
Jun 03 20158 years fee payment window open
Dec 03 20156 months grace period start (w surcharge)
Jun 03 2016patent expiry (for year 8)
Jun 03 20182 years to revive unintentionally abandoned end. (for year 8)
Jun 03 201912 years fee payment window open
Dec 03 20196 months grace period start (w surcharge)
Jun 03 2020patent expiry (for year 12)
Jun 03 20222 years to revive unintentionally abandoned end. (for year 12)